TherapeuticsMD (TXMD) Accounts Payables (2010 - 2026)

TherapeuticsMD (TXMD) has reported Accounts Payables for 17 consecutive years, with $460000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables rose 31.43% year-over-year to $460000.0; the trailing twelve-month figure through Jun 2026 stood at $460000.0 (up 31.43% YoY), and the FY2025 full-year result was $377000.0, up 46.12% from the prior year.
• Accounts Payables climbed to $460000.0 in Q2 2026 per TXMD's latest filing, from $15000.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $20.8 million in Q1 2022 and bottomed at $15000.0 in Q1 2026.
• Historically, Accounts Payables has averaged $3.2 million across 5 years, with a median of $363500.0 in 2025.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables plunged 98.75% in 2023, then surged 855.56% in 2024.
• Over 5 years, Accounts Payables stood at $2.2 million in 2022, then slumped by 98.75% to $27000.0 in 2023, then soared by 855.56% to $258000.0 in 2024, then jumped by 46.12% to $377000.0 in 2025, then climbed by 22.02% to $460000.0 in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $460000.0, $15000.0, and $377000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.